Medivir (MVIR.ST)

Executive Summary

Medivir is a Swedish drug discovery and development company focused on transformative cancer therapies, leveraging expertise in protease inhibitor design and nucleoside/nucleotide science. The company's lead asset, remetinostat, is a topical HDAC inhibitor in Phase 3 for early-stage cutaneous T-cell lymphoma (CTCL), a niche indication with high unmet need. Additionally, fostroxacitabine briofens (fostrox), a liver-targeted nucleoside analog, is in Phase 2 for hepatocellular carcinoma (HCC), addressing a large market. Medivir's pipeline also includes early-stage protease inhibitor programs. With a market cap of ~$967 million, the company is well-positioned to advance its clinical candidates, though it faces typical biotech risks including regulatory hurdles and competition. Key upcoming catalysts include Phase 3 data for remetinostat and Phase 2 updates for fostrox.

Upcoming Catalysts (preview)

• Q3 2026Phase 3 enrollment completion for remetinostat in CTCL70% success
• Q3 2026Phase 2 data update for fostrox in HCC50% success
• TBDPotential partnership or licensing deal for pipeline assets60% success